Human primary co-culture angiogenesis assay reveals additive stimulation and different angiogenic properties of VEGF and HGF

被引:34
作者
Beilmann, M
Birk, G
Lenter, MC
机构
[1] Boehringer Ingelheim Pharma GmbH & Co KG, Mol & Cell Toxicol Grp, Dept Nonclin Drug Safety, D-88397 Biberach, Germany
[2] Boehringer Ingelheim Pharma GmbH & Co KG, Genom & Prote Grp, Dept Pulm Dis, D-88397 Biberach, Germany
关键词
angiogenesis; HGF; image analysis; MET; vascular development;
D O I
10.1016/j.cyto.2004.03.003
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Therapeutic angiogenesis aims to induce blood vessel growth in acute or chronic ischemic tissues and has gained tremendous interest over the last years. To study factors and combinations thereof that potentially induce or modify angiogenesis and to evaluate their therapeutic potential, various in vitro assays have been developed. Although endothelial cells have attracted most attention in these assays, they alone cannot complete vessel maturation since extracellular matrix (ECM) components and mesenchymal cells also play an important role in vascular development. To address this complexity we focussed on a human co-culture angiogenesis assay comprising primary endothelial cells as well as primary ECM-producing fibroblasts. In this assay HGF and VEGF as single factors and combined were tested for the potential to induce an angiogenic response, which was detected by image analysis assessing the area, length and branches of the formed vascular structures. The results show that the cytokines HGF and VEGF both promote angiogenesis in this co-culture assay by inducing distinguishable patterns of vascular structures. VEGF increases the length, area and branch point number of induced vessels whereas HGF mediates exclusively vascular area growth resulting in vascular structures of enlarged diameter. Moreover, the combination of both cytokines results in an additive increase of vascular diameter. (C) 2004 Elsevier Ltd. All rights reserved.
引用
收藏
页码:178 / 185
页数:8
相关论文
共 20 条
  • [1] An in vitro model of angiogenesis: Basic features
    Bishop E.T.
    Bell G.T.
    Bloor S.
    Broom I.J.
    Hendry N.F.K.
    Wheatley D.N.
    [J]. Angiogenesis, 1999, 3 (4) : 335 - 344
  • [2] HEPATOCYTE GROWTH-FACTOR IS A POTENT ANGIOGENIC FACTOR WHICH STIMULATES ENDOTHELIAL-CELL MOTILITY AND GROWTH
    BUSSOLINO, F
    DIRENZO, MF
    ZICHE, M
    BOCCHIETTO, E
    OLIVERO, M
    NALDINI, L
    GAUDINO, G
    TAMAGNONE, L
    COFFER, A
    COMOGLIO, PM
    [J]. JOURNAL OF CELL BIOLOGY, 1992, 119 (03) : 629 - 641
  • [3] TUMOR VASCULAR-PERMEABILITY FACTOR STIMULATES ENDOTHELIAL-CELL GROWTH AND ANGIOGENESIS
    CONNOLLY, DT
    HEUVELMAN, DM
    NELSON, R
    OLANDER, JV
    EPPLEY, BL
    DELFINO, JJ
    SIEGEL, NR
    LEIMGRUBER, RM
    FEDER, J
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 1989, 84 (05) : 1470 - 1478
  • [4] Comparison of three in vitro human 'angiogenesis' assays with capillaries formed in vivo
    Donovan D.
    Brown N.J.
    Bishop E.T.
    Lewis C.E.
    [J]. Angiogenesis, 2001, 4 (2) : 113 - 121
  • [5] A target-mediated model to describe the pharmacokinetics and hemodynamic effects of recombinant human vascular endothelial growth factor in humans
    Eppler, SM
    Combs, DL
    Henry, TD
    Lopez, JJ
    Ellis, SG
    Yi, JH
    Annex, BH
    McCluskey, ER
    Zioncheck, TF
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2002, 72 (01) : 20 - 32
  • [6] VEGF and the quest for tumour angiogenesis factors
    Ferrara, N
    [J]. NATURE REVIEWS CANCER, 2002, 2 (10) : 795 - 803
  • [7] TUMOR DORMANCY IN-VIVO BY PREVENTION OF NEOVASCULARIZATION
    GIMBRONE, MA
    COTRAN, RS
    FOLKMAN, J
    LEAPMAN, SB
    [J]. JOURNAL OF EXPERIMENTAL MEDICINE, 1972, 136 (02) : 261 - &
  • [8] Gene therapy progress and prospects: therapeutic angiogenesis for limb and myocardial ischemia
    Khan, TA
    Sellke, FW
    Laham, RJ
    [J]. GENE THERAPY, 2003, 10 (04) : 285 - 291
  • [9] Kuba K, 2000, CANCER RES, V60, P6737
  • [10] Therapeutic angiogenesis with recombinant fibroblast growth factor-2 for intermittent claudication (the TRAFFIC study): a randomised trial
    Lederman, RJ
    Mendelsohn, FO
    Anderson, RD
    Saucedo, JF
    Tenaglia, AN
    Hermiller, JB
    Hillegass, WB
    Rocha-Singh, K
    Moon, TE
    Whitehouse, MJ
    Annex, BH
    [J]. LANCET, 2002, 359 (9323) : 2053 - 2058